Gene and Cell Therapy. Code: ECTS Credits: 6. Degree Type Year Semester Biomedical Sciences OT 4 0

Similar documents
Genetically Modified Animals. Code: ECTS Credits: 6. Degree Type Year Semester Biomedical Sciences OT 4 0

Cell and Gene Therapy Catapult clinical trials database

Code: ECTS Credits: 9. Degree Type Year Semester Advanced Biotechnology OT 0 1

Basic Microbiology and Virology. Code: ECTS Credits: 3. Degree Type Year Semester Biomedical Sciences OB 1 2

Transgenesis and Gene Therapy: from Animal to Clinic

Transgenesis and Gene Therapy: from the Animal to the Clinic

Genetic Engineering of Microorganisms. Code: ECTS Credits: 6. Degree Type Year Semester

The Cell and Gene Therapy Catapult UK clinical trials database

Genetics and Genomics in Medicine Chapter 9 Questions

Recombinant DNA: Basics and Advanced Applications

Recombinant DNA: Basics and Advanced Applications

The Cell and Gene Therapy Catapult UK clinical trials database

Sangamo Therapeutics Announces Presentations at 2017 Annual meeting of the American Society of Gene & Cell Therapy

Environmental Microbiology. Code: ECTS Credits: 6. Degree Type Year Semester Environmental Biology OT 4 0

1. COURSE TITLE INTERACTION DRUG ORGANISM Course number Content area Course type Course level Year. 1.6.

ANNOUNCEMENTS. HW2 is due Thursday 2/4 by 12:00 pm. Office hours: Monday 12:50 1:20 (ECCH 134)

ICH Considerations on Viral/Vector Shedding; and Overview of Gene Therapy Activity in Canada

Gene Therapy for Fanconi Anaemia Hope or hype? Dr Phil Ancliff Great Ormond Street Hospital / UCL Institute of Child Health Twycross Zoo October 2017

JUST THE FACTS 1. Nearly 300 Cell and Gene Therapies in Development for A Broad Range of Diseases

Recombinant DNA: Basics and Advanced Applications. Code: ECTS Credits: 9. Degree Type Year Semester

Ecotoxicology and Pollution. Code: ECTS Credits: 10. Degree Type Year Semester Environmental Biology OB 3 1

Cellular and Gene Therapy Products - CBER Update

Teachers: María Jesús Bullido (CBMSO-UAM/CSIC) - coordinator Tel

Hemophilia and Gene Therapy

COURSE GUIDE Universidad Católica de Valencia Pharmaceutical Engineering and Drug Design THIS SUBJECT IS NOT OFFERED DURING THIS ACADEMIC YEAR

Gene therapy. Findings by Alert

Molecular Pharmacology. Code: ECTS Credits: 6. Degree Type Year Semester

ANAT 2341 Embryology Lecture 18 Stem Cells

ICH Considerations. Oncolytic Viruses September 17, 2009

Pioneering the Development of Safe and Effective Non-Viral Vectors and Processes for Human Gene Therapy and DNA Vaccination.

Gene Therapy: The Basics. Mark A. Kay MD PhD Dennis Farrey Family Professor Stanford University

Stem Cells: Introduction and Prospects in Regenerative Medicine.

DB3230 Midterm 1 11/15/2013 Name:

Module BIO 628 Spring term 2015

Course Agenda. Day One

Lecture 7 Adeno-associated viral vectors

HUMAN GENOME EDITING FAQs

Gene Therapy and Emerging Molecular Therapies

10/07/2018. Liver directed gene therapy. - An overview. DNA/RNA therapies for Wilson s disease. The liver, organ of choice. Highly vascularised

COURSE GUIDE Universidad Católica de Valencia Pharmacology and Toxicology

Pioneering the Development of Safe and Effective Non-Viral Vectors and Processes for Human Gene Therapy and DNA Vaccination.

ICH Considerations Oncolytic Viruses ONCOLYTIC VIRUSES (EMEA/CHMP/ICH/607698/2008) TRANSMISSION TO CHMP November 2008

COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) <DRAFT>

Molecular Medicine. Stem cell therapy Gene therapy. Immunotherapy Other therapies Vaccines. Medical genomics

Genome Editing Technology - Principle -

Gene Expression. Chapters 11 & 12: Gene Conrtrol and DNA Technology. Cloning. Honors Biology Fig

CHANGES TO A GENE THERAPY MEDICINAL PRODUCT: REGULATORY VIEWS

Genetic Basis of Development & Biotechnologies

Unit 1: DNA and the Genome. Sub-Topic (1.4) Cellular Differentiation

Welcome to the Webinar! Human Genome Editing: Latest Developments and Advancements

Stem cells in Development

Lectures 28 and 29 applications of recombinant technology I. Manipulate gene of interest

Stem cells in Development

Regulatory Requirements for CRISPR Therapeutics. Bill Lundberg, MD February 2017

UNDERSTANDING GENE REPLACEMENT THERAPY FOR GENETIC DISEASES

Baculovirus Adenovirus Adeno-associated virus Lentivirus/Retrovirus Many more: Vaccinia virus, Semliki Forest virus

New Regulation for Advanced Therapies including Oncology Biological Products. isbtc Global Regulatory Summit

240EQ222 - Genetic Engineering

REGISTRATION DOCUMENT FOR RECOMBINANT DNA RESEARCH

Des cellules-souches dans le poumon : pourquoi faire?

Development Stage of Therapeutic Vaccines: The Regulator s View

FDA Update. Scott A. Brubaker, CTBS Director, Division of Human Tissues Office of Tissues and Advanced Therapies CBER/FDA

Lisa Griffin (BSc Hons Biology), David Hughes August 2013

City University of Hong Kong. Information on a Course offered by Department of Biology and Chemistry with effect from Semester A 2015 / 2016

ICH CONSIDERATIONS Oncolytic Viruses

Direction of Logistical Operations. Code: ECTS Credits: 6. Degree Type Year Semester Aeronautical Management OT 4 0

Course Justifications for ANSC 650 (DNA and Genetic Analysis) 1. What is the new course?

Degree in Biotechnology. Genetically Modified Organisms. Type: Compulsory Credits ECTS: 6. Applied Biotechnology

COURSE CATALOGUE UH SEMESTER 3

Duncanrig Secondary School

Biological Research Registration Form

BIS 2041 Business Process Management and Transactional Process Systems (BpmT)

AGR 5307: Molecular Genetics for Crop Improvement Course Objectives: Learning Outcomes: 65 % lectures 15 % laboratory demonstrations 15 % papers 5 %

sirna Overview and Technical Tips

Presenter: Teresa Holm

Issues in production of viral gene transfer vectors. Stefan Kochanek Department of Gene Therapy Ulm University

Cloning. 1. What is cloning: Natural and artificial 2. Cloning of what? 3. Embryonic development of multi-cellular organisms:

ISTINYE UNIVERSITY INSTITUTE OF HEALTH SCIENCES DEPARTMENT OF STEM CELL AND TISSUE ENGINEERING (THESIS) COURSE DESCRIPTIONS

FDA Oversight of Gene Therapy

Microbial Biotechnology Doctorate Program Specification (2015/ 2016)

Financial Statements Analysis

Biology 142 Advanced Topics in Genetics and Molecular Biology Course Syllabus Spring 2006

Biology 252 Nucleic Acid Methods

Basic Concepts and History of Genetic Engineering. Mitesh Shrestha

Yale University Biological Safety Committee

AQA Biology A-level Topic 8: The control of gene expression

Includes 'study abroad' Description This lecture module will introduce the following topics: Assessment Assessment Type Exam 1 (100%) Convenor

University of Delaware Department of Environmental Health & Safety Recombinant DNA Registration

Clinical Development of Gene Therapy: Safety Evaluation and Monitoring

Chapter 20: Biotechnology

PhysicsAndMathsTutor.com. Question Number. Answer Additional guidance Mark. 1(a) 1. reference to stem cells being {totipotent / pluripotent} ;

Registration Document For Biohazards

Medical Topics: Gene Therapy. E. Anne Jackson, FSA MAAA July 30, 2018

Future of Stem Cell Engineering. Jaeseung Jeong, Ph.D Department of Bio and Brain Engineering KAIST

Edexcel (B) Biology A-level

This presentation contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform

GTA Name: Bo Pan GTA GTA office location and office hours: Room 133, ANNU Building; by appointment.

TISSUE ENGINEERING AND REGENERATION: TECHNOLOGIES AND GLOBAL MARKETS

REMEDiE Project London 7-8 May 2009 European Policies and Priorities for Stem Cell Research

Beth Hutchins, PhD PhRMA ICH Gene Therapy Discussion Group

Transcription:

2018/2019 Gene and Cell Therapy Code: 101920 ECTS Credits: 6 Degree Type Year Semester 2501230 Biomedical Sciences OT 4 0 Contact Name: Maria Fátima Bosch Tubert Email: Fatima.Bosch@uab.cat Teachers Use of languages Principal working language: catalan (cat) Some groups entirely in English: No Some groups entirely in Catalan: Yes Some groups entirely in Spanish: No Pedro José Otaegui Goya Miguel García Martínez Federico Mingozzi Ivet Elias Puigdomenech Verónica Jiménez Cenzano Prerequisites There are no prerequisites to attend this course. However, to facilitate the student's understanding of the subject matter and the achievement of the learning goals proposed, it is advisable that the student has previous knowledge on Cellular Biology, Genetics, Molecular Biology and Recombinant DNA technology. It is also advisable that the students have basic knowledge of English, so that they can use the information sources of the field, which are mostly in this language. Objectives and Contextualisation The objective of the subject "Gene and Cell Therapy" is to provide the students with up-to-date knowledge in the methodologies available for the genetic engineering of cells for therapeutic purposes. Thus, the content of the subject will cover the following topics: Description of in vivo and ex vivo gene therapy; Study of the different vectors used for viral and non-viral gene transfer and their respective advantages and shortcomings; study of the possible routes of administration of the vectors and the applications to the treatment of hereditary and non-hereditary human diseases. Description of cell therapy. Transplant of fully differentiated somatic cells (pancreatic islets, hepatocytes, and bone marrow). Transplant of pluripotent stem cells (embryonic and adult). Sources of cells for cell therapies. Therapreutic applications of cell therapies. Biosafety, ethics and legal aspects associated to the use of cell therapies in humans. Skills Contribute to public discussions on cultural matters. 1

Develop independent learning habits and motivation to continue training at postgraduate level. Develop scientific knowledge, critical reasoning and creativity. Display knowledge of techniques related to genetic and reproductive technologies. Identify and understand the advances and challenges of research. Read and critically analyse original and review papers on biomedical issues and assess and choose the appropriate methodological descriptions for biomedical laboratory research work. Show respect for the ethical and legal aspects of research and professional activities. Work as part of a group with members of other professions, understanding their viewpoint and establishing a constructive collaboration. Learning outcomes 1. 2. 3. 4. 5. 6. 7. 8. 9. 10. 11. Contribute to public discussions on cultural matters. Develop independent learning habits and motivation to continue training at postgraduate level. Develop scientific knowledge, critical reasoning and creativity. Display knowledge of techniques related to genetic and reproductive technologies. Explain the pathogenesis associated with reproductive processes. Identify and understand the advances and challenges of research. Read specialised texts both in English and ones own language Recognise the ethical principles and current legislation in relation to animal genetic manipulation and animal experimentation, gene therapy and reproduction techniques, in their application to biomedicine. Search for and manage information from various sources Show respect for the ethical and legal aspects of research and professional activities. Work as part of a group with members of other professions, understanding their viewpoint and establishing a constructive collaboration. Content Knowledge on the following topics will be imparted during the theoretical classes: TOPIC 1 Molecular basis of Gene Therapy. Gene therapy in vivo and ex vivo. Introduction to Cell therapy. TOPIC 2 Retroviral vectors derived from murine leukaemia virus. Retroviral replicative cycle. Production of retroviral vectors. Retrovirus-mediated gene expression. Applications. TOPIC 3 Lentiviral vectors (LV). Genomic organization of lentiviruses. Production of lentiviral vectors. Properties. Applications. TOPIC 4 Adenoviral vectors (Ad). Structure and genomic organization of adenoviruses. Production of adenoviral vectors. Properties. Applications. Production of less immunogenic later generation adenoviral (HD-Ad). Oncolytic adenoviral vectors. TOPIC 5 Adeno-associated viral vectors (AAV). Biology of adeno-associated viruses. Production of adeno-associated virus-derived recombinant vectors. Properties. Applications. TOPIC 6 2

Non-viral vectors (I). Use of cationic liposomes in gene therapy. Gene transfer with cationic polymers. Receptor-mediated gene transfer. TOPIC 7 Non-viral vectors (II). Transfer of plasmidic DNA in solution to the muscle. Electrotransfer. Transfer of plasmidic DNA in solution to the liver through hydrodynamic procedures. Applications. TOPIC 8 Interference RNA (sirna). Gene therapy based on the use of sirna. Applications. TOPIC 9 Genome editing. Different types of nucleases: Meganucleases, Zinc-finger nucleases, TALENs, CRISPR Technologies. Applications in the field of Gene Therapy. TOPIC 10 Ex vivo TOPIC 11 gene therapy; hematopoietic stem cells. Introduction to Embryonic Stem Cells ( ES cells). Differentiation of cells. Clinical Applications of ES cells. TOPIC 12 Adult stem cells and their applications. TOPIC 13 Reprogramming and Induced Pluripotent Stem Cells (ips). TOPIC 14 Gene therapy for hereditary monogenic diseases: Immunedeficiencies. Lysosomal diseases. Cystic fibrosis. Eye diseases. Haemophilia. Muscular dystrophies. Other diseases. TOPIC 15 Gene therapy for cancer. Immunotherapies. Use of suicide genes. Antiangiogenic gene therapies. Use of tumour suppressor genes. Use of antisense sequences. Other therapeutic strategies. TOPIC 16 Gene therapy for diabetes mellitus. Gene therapy for cardiovascular diseases. Gene therapy for neurodegenerative diseases.gene therapy for infectious diseases (AIDS, hepatitis). DNA vaccines. TOPIC 17 Cell therapies for the regeneration of bone and cartilage. TOPIC 18 Cell therapies for the regeneration of skin. Cell therapies for the regeneration of eye diseases. TOPIC 19 Cell therapies for Parkinson disease and other Central Nervous System diseases. 3

TOPIC 20 Cell therapies for diabetes mellitus and cardiovascular diseases. TOPIC 21 Cell and Gene Therapy Clinial protocols. Phases of a clinical trial. European regulatory bodies, American regulatory bodies. Ethical aspects of gene and cell therapies. Three exercises are proposed for the laboratory practice classes. The first assignment is the design of a gene or cell therapy strategy for a given disease, from design of the gene or cell product to proof-of-concept studies and translational studies that allow a clinical trial in humans.this exercise is proposed as a review of all the concepts introduced in the theory classes. The second proposed activity allows students to acquire experience in the use of laboratory animals in gene and cell therapy studies. Finally, in the third proposed activity we show students how to perform a partial hepatectomy for gene therapy approaches directed to the liver. Content of the laboratory practice classes: - Design of a gene or cell therapy strategy; discussion of the different options. - Introduction to the use of laboratory animals in gene and cell therapy studies. - Methods and routes of administration of viral and non-viral vectors. Methodology The subject "Gene and Cell Therapy" consists of theory and laboratory classes, and tutored oral presentations of relevant literature. The formative activities of the subject are complementary. Theoretical classes The contents of the theoretical classes will be imparted by a Professor in a series of master classes supported by audio-visual material. The slides used by each professor in each class will be available to the students through the subject's Campus Virtual/Moodle. These master classes will constitute the main form of transfer of theoretical contents. Students are advised to periodically consult the books and links suggested in the Bibliography section of this document and at the Campus Virtual/Moodle to consolidate and clarify, if necessary, the contents explained in class. Laboratory practice classes The laboratory practice classes have been designed to help students get familiarized with the methodologies used in the field of gene therapy and have a direct experience in the handling of laboratory animals for gene therapy studies. We expect that, during these laboratory practice classes, students will be able to experience a "real world" experimental situation. We would like students to experience the excitement associated to research in the field of gene therapy. The laboratory practice classes are composed of 3 sessions of 4 h each (from 3PM to 7PM), during which students will work in groups of 2 people under the supervision of an experienced professor. The dates assigned to each laboratory practice group will be published in the subject's Campus Virtual/Moodle with sufficient anticipation. Attendance to laboratory practice classes is mandatory. The laboratory practice guide will be available through the Campus Virtual/Moodle. Students must bring their own lab coat, a waterproof marker and the Laboratory Practice Guide to each laboratory practice class. Oral presentations of selected papers 4

Students will analyse and discuss in an oral presentation in front of the whole class a selected recent scientific publication on gene or cell therapy published in a recognized international scientific journal. To this end, students will pair with a fellow classmate. During the process of analysis of the paper's content and preparation of the oral presentation, students will be tutored by researchers with experience in the field of gene and cell therapy. Students will have 10 minutes for the oral presentation, equally divided amongst the members of the group, plus 5 minutes for questions (total of 15 minutes). The objective of this evaluating activity is that students get used -under the supervision of a tutor- to the process of searching, reading and understanding of scientific literature, and if necessary, develop a critical view on the figures, tables and results described in the publication. On the other hand, with this activity students will increase their knowledge of the current applications of gene and cell therapy technologies. Tutoring The oral presentations of selected papers will be tutored. In addition, upon request from the students, individualized tutoring will be available throughout the course. The objective of this sessions will be to help the student resolve doubts and review basic concepts and to provide them with advice on sources of information and the best way to discuss scientific results in public. Activities Title Hours ECTS Learning outcomes Type: Directed Oral presentations 9 0.36 1, 4, 3, 2, 5, 8, 11 Practical lessons 12 0.48 10, 1, 4, 6, 8, 11 Theorical lessons 34 1.36 1, 3, 5, 6, 7, 11 Type: Supervised Tutorials 5 0.2 10, 4, 3, 6, 8, 11 Type: Autonomous Individual study time 74 2.96 9, 4, 3, 2, 6, 7, 8 Oral presentations 10 0.4 9, 4, 3, 2, 6, 7, 11 Evaluation To pass the course, students must achieve a final score of 5 points (over a total of 10 points) and must attend the laboratory practice classes. The evaluation activities are: 1.- Final examination of theoretical classes Accounts for 50% of the final score (5 points out of 10). Assessment will consist of a written examination, under the format of a True or False test, on topics explained during the theoretical classes. A score greater than 2.5 in this examination is required to pass the course. There will be a Second Chance/Recovery Exam, under the same format as the original exam. 2.- Examination of Laboratory classes Accounts for 15% of the final score (1.5 points out of 10). Assessment will consist of a written examination, under the format of a True or False test, on topics explained during the practical classes. It will be held at the 5

end of practical classes period. To pass the subject, attendance at the practical classes is mandatory. 3.- Self-study exercise Accounts for 10% of the final score (1 point out of 10). Assessment will consist of an exercise that the student will have to develop on their own. Details will be posted online in the "Campus Virtual" at the end of April. 4.- Oral presentations of selected research papers Accounts for 15% of the final score (1.5 points out of 10). Students will be evaluated individually, both on their performance during the oral presentation of the selected paper and on the audio-visual material that they prepared to support their group presentation. 5.- Attendance to the oral presentations of research papers Accounts up to 10% of the final score (1 point out of 10). Both attendance and participation in the scientific discussions of the sessions will be evaluated, following the scale: Attendance 90-100% = 1 point Attendance 80-89% = 0,8 points Attendance 70-79% = 0,7 points Attendance 60-69% = 0,6 points Attendance 50-59% = 0,5 points Attendance 0-49% = 0 points Students will be deemed Non-Qualifiable if the number of evaluating activities in which they participate is less than 50% of those proposed in this guide. Evaluation activities Title Weighting Hours ECTS Learning outcomes Attendance to the oral presentations of research papers 10% 0 0 10, 9, 1, 4, 3, 2, 6, 7, 8 Examination of Laboratory classes 15% 1 0.04 10, 9, 1, 4, 3, 2, 6, 7, 8, 11 Final examination of theoretical classes 50% 3 0.12 10, 9, 1, 4, 3, 2, 5, 6, 7, 8 Oral presentations of selected research papers 15% 1 0.04 10, 9, 1, 4, 3, 2, 6, 7, 8, 11 Self-study exercise 10% 1 0.04 10, 9, 1, 4, 3, 2, 6, 7, 8, 11 Bibliography 1- Gene and Cell Therapy. Therapeutic Mechanisms and Strategies. 2nd Edition. Edited by Nancy Smyth Templeton. Marcel Dekker, Inc. 2004. 6

2- Gene Therapy technologies, aplications and regulations. From Laboratory to Clinic. Edited by Anthony Meager. John Wiley & Sons, LTD. 1999. 3- Gene Therapy Protocols. 2 nd Edition. Edited by Jeffrey R. Morgan. Humana Press. 2002. 4- Human Molecular Genetics 2. T. Strachan i A.P. Read. John Wiley & Sons, Inc., Publication. 1999. 5- Cell Therapy. D. Garcia-Olmo, J.M. Garcia-Verdugo, J. Alemany, J.A. Gutierrez-Fuentes. McGraw-Hill Interamericana. 2008. 6- Gene and Cell Therapy. Therapeutic Mechanisms and Strategies. Second edition, Revised and Expanded. N.S. Templeton. Marcel Dekker, Inc. 2004. 7